[go: up one dir, main page]

SMT201800533T1 - Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi - Google Patents

Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi

Info

Publication number
SMT201800533T1
SMT201800533T1 SM20180533T SMT201800533T SMT201800533T1 SM T201800533 T1 SMT201800533 T1 SM T201800533T1 SM 20180533 T SM20180533 T SM 20180533T SM T201800533 T SMT201800533 T SM T201800533T SM T201800533 T1 SMT201800533 T1 SM T201800533T1
Authority
SM
San Marino
Prior art keywords
tudca
treatment
neurodegenerative disorders
tauroursodeoxycholic acid
tauroursodeoxycholic
Prior art date
Application number
SM20180533T
Other languages
English (en)
Inventor
Gilberto Rinaldi
Original Assignee
Bruschettini Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48949193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201800533(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bruschettini Srl filed Critical Bruschettini Srl
Publication of SMT201800533T1 publication Critical patent/SMT201800533T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM20180533T 2013-07-01 2013-07-01 Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi SMT201800533T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13747521.6A EP3016654B2 (en) 2013-07-01 2013-07-01 Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders
PCT/IB2013/055383 WO2015001379A1 (en) 2013-07-01 2013-07-01 Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
SMT201800533T1 true SMT201800533T1 (it) 2018-11-09

Family

ID=48949193

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20180533T SMT201800533T1 (it) 2013-07-01 2013-07-01 Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi

Country Status (16)

Country Link
EP (1) EP3016654B2 (it)
CN (2) CN105358147A (it)
CY (1) CY1120835T1 (it)
DK (1) DK3016654T3 (it)
ES (1) ES2691408T3 (it)
HR (1) HRP20181554T1 (it)
HU (1) HUE040027T2 (it)
LT (1) LT3016654T (it)
PL (1) PL3016654T3 (it)
PT (1) PT3016654T (it)
RS (1) RS57763B1 (it)
RU (1) RU2016102092A (it)
SI (1) SI3016654T1 (it)
SM (1) SMT201800533T1 (it)
TR (1) TR201815345T4 (it)
WO (1) WO2015001379A1 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
BR112022011951A2 (pt) * 2019-12-16 2022-09-06 Amylyx Pharmaceuticals Inc Tratamento de esclerose lateral amiotrófica e distúrbios relacionados
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
AU2021219072B2 (en) * 2020-02-13 2024-10-03 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
CN112972480A (zh) * 2021-03-09 2021-06-18 兆科药业(广州)有限公司 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
CN120659782A (zh) * 2023-02-15 2025-09-16 深圳君圣泰生物技术有限公司 小檗碱牛磺熊去氧胆酸盐组合物及其方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1770975A (zh) * 2003-04-02 2006-05-10 明尼苏达大学评议会 提高细胞生存能力的方法
CA2581126A1 (en) * 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
CA2585471A1 (en) * 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
ES2358089T3 (es) * 2004-11-01 2011-05-05 Seo Hong Yoo Métodos y composiciones para reducir la neurodegeneración en esclerosis lateral amiotrófica.
JP2008530100A (ja) 2005-02-10 2008-08-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 視覚障害の治療方法
US20110142799A1 (en) 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
EP2422787A1 (en) * 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)

Also Published As

Publication number Publication date
WO2015001379A1 (en) 2015-01-08
RS57763B1 (sr) 2018-12-31
CN109999030A (zh) 2019-07-12
DK3016654T3 (en) 2018-11-05
EP3016654B1 (en) 2018-09-05
LT3016654T (lt) 2018-11-12
CN105358147A (zh) 2016-02-24
TR201815345T4 (tr) 2018-11-21
CY1120835T1 (el) 2019-12-11
PL3016654T3 (pl) 2019-02-28
HRP20181554T1 (hr) 2018-12-14
PT3016654T (pt) 2018-11-09
SI3016654T1 (sl) 2019-05-31
EP3016654A1 (en) 2016-05-11
EP3016654B2 (en) 2025-11-12
HUE040027T2 (hu) 2019-02-28
ES2691408T3 (es) 2018-11-27
RU2016102092A (ru) 2017-08-04

Similar Documents

Publication Publication Date Title
IL273815B (en) Secondary vaccine particles for the treatment of inflammation
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
SMT202000346T1 (it) 19-norsteroidi neuroattivi per metodi di trattamento
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
EP3068492A4 (en) Neurodegenerative disorders and methods of treatment and diagnosis thereof
IL241191A0 (en) Local compositions and methods for treating local disorders
PL2838539T3 (pl) Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych
SMT201800533T1 (it) Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
EP3038707A4 (en) Treatment of pediatric otic disorders
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
EP2941252A4 (en) USE OF FATTY ACID NIACIN CONJUGATES FOR THE TREATMENT OF DISEASES
EP3013824B8 (en) Carboline compounds usable in the treatment of neurodegenerative diseases
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
IL236993A0 (en) A liquid substance to administer for the treatment of dermatophytosis
ZA201507724B (en) The treatment of inflammatory disorders
EP2958570A4 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS
HUE058845T2 (hu) Nem biokonvertibilis C3-szubsztituált pregnenolon-származékok szerhasználati zavarok kezelésében történõ alkalmazásra
HUE045296T2 (hu) Epesavat tartalmazó gyermekgyógyászati készítmény
IL245613B (en) Peptides for use in the treatment of inflammatory diseases that are not related to pathogenic factors
AU2013901514A0 (en) Formulation and methods for treatment of mental disorders
GB201308539D0 (en) Liquid treatment
GB201310590D0 (en) Wheelchair with various assistance elements